OCS Stock Price | Oculis Holding AG Ordinary shares P/E, Revenue, EPS, & Forecasts

Oculis Holding AG Ordinary shares • OCS

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Oculis Holding AG Ordinary shares

Ticker

OCS

Trading on

NASDAQ

ISIN

CH1242303498

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Riad Sherif M.B.A., M.D.

Headquarters

Bahnhofstrasse 20, Zug, undefined, Switzerland, 6300

Employees

Website

https://oculis.com

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Metrics

BasicAdvanced

Market cap

$1.04B

P/E ratio

EPS

-$2.90

Dividend Yield

0.00%

Beta

0.14

Forward P/E ratio

EBIDTA

$-77.4M

Ex dividend date

Price & volume

Market cap

$1.04B

Average daily volume

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

1,384.57

Price to book

5.22

Earnings

EPS

-$2.90

EPS estimate (current quarter)

-$0.40

EPS estimate (next quarter)

-$0.38

EBITDA

$-77.4M

Revenues (TTM)

$0.7M

Revenues per share (TTM)

$0.02

Technicals

Beta

0.14

52-week High

$23.08

52-week Low

$10.79

50-day moving average

$18.07

200-day moving average

$17.16

Short ratio

0.56

Short %

0.04%

Management effectiveness

ROE (TTM)

-85.16%

ROA (TTM)

-32.13%

Profit margin

0.00%

Gross profit margin

$-55.2M

Operating margin

-7,008.42%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

28.40%

Share stats

Outstanding Shares

52.1M

Float

41.2M

Insiders %

6.35%

Institutions %

30.98%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 7 analysts.

Average price target

$37.26

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.51

-$0.37

-36.58%

Q2 • 24Missed

-$0.48

-$0.42

-13.37%

Q3 • 24Missed

-$0.67

-$0.42

-60.79%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-28.7M

-∞%

Q4 • 24

$0M

$-33.2M

-∞%

Q1 • 25

NaN%

15.91%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$120M

$47M

39.03%

Q4 • 24

$204M

$41.5M

20.35%

Q1 • 25

69.64%

-11.55%

-47.86%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-10.4M

$-1.1M

$2.7M

$-10.4M

Q4 • 24

$-19M

$-51.5M

$104M

$-20.1M

Q1 • 25

83.08%

4,519.28%

3,734.23%

92.64%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Oculis Holding AG Ordinary shares share?

Oculis Holding AG Ordinary shares shares are currently traded for undefined per share.

How many shares does Oculis Holding AG Ordinary shares have?

Oculis Holding AG Ordinary shares currently has 52.1M shares.

Does Oculis Holding AG Ordinary shares pay dividends?

No, Oculis Holding AG Ordinary shares doesn't pay dividends.

What is Oculis Holding AG Ordinary shares 52 week high?

Oculis Holding AG Ordinary shares 52 week high is $23.08.

What is Oculis Holding AG Ordinary shares 52 week low?

Oculis Holding AG Ordinary shares 52 week low is $10.79.

What is the 200-day moving average of Oculis Holding AG Ordinary shares?

Oculis Holding AG Ordinary shares 200-day moving average is $17.16.

Who is Oculis Holding AG Ordinary shares CEO?

The CEO of Oculis Holding AG Ordinary shares is Dr. Riad Sherif M.B.A., M.D..

How many employees Oculis Holding AG Ordinary shares has?

Oculis Holding AG Ordinary shares has 49 employees.

What is the market cap of Oculis Holding AG Ordinary shares?

The market cap of Oculis Holding AG Ordinary shares is $1.04B.

What is the P/E of Oculis Holding AG Ordinary shares?

The current P/E of Oculis Holding AG Ordinary shares is null.

What is the EPS of Oculis Holding AG Ordinary shares?

The EPS of Oculis Holding AG Ordinary shares is -$2.90.

What is the PEG Ratio of Oculis Holding AG Ordinary shares?

The PEG Ratio of Oculis Holding AG Ordinary shares is null.

What do analysts say about Oculis Holding AG Ordinary shares?

According to the analysts Oculis Holding AG Ordinary shares is considered a buy.